The outbreak of Ebola virus disease in west Africa in 2013-16 showed that the world is not suffi ciently prepared to detect and respond to epidemic threats. It exposed a systemic need for stronger operational and strategic capabilities in infectious disease response, and for the development of more eff ective tools and technologies to manage, treat, and prevent disease. Evaluations of the Ebola response highlight that the global community must rethink how vaccines, diagnostics, and drugs for emerging infections are developed given their lack of commercial profi tability, especially since outbreaks are most likely to occur in resource-constrained environments. 1 Two Ebola panels called for a new global fi nancing mechanism to invest US$1 billion annually; all panels recommended a strong normative and convening role for WHO. 1 WHO has duly initiated a research and development (R&D) Blueprint to coordinate its own and other stakeholders' work on product-relevant R&D for infectious diseases with epidemic potential. 2 A network of research funding organisations, the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R), has been initiated by the European Commission to coordinate rapid research response to public health emergencies. 3 But there remains an urgent need for entities that can facilitate pooled funding and implementation of R&D for epidemic preparedness on a global scale, since these are not among WHO's core functions.
In January, 2016, the World Economic Forum convened a group of representatives to explore the way forward, with vaccine development as the starting focus.
The Ebola epidemic had shown that fast-track and collaborative development of vaccines was possible. More than 15 clinical vaccine trials (phase 1, 2, and 3) were planned and implemented within a year from August, 2014, and the ring vaccination trial in Guinea showed eff ectiveness of the replication-competent recombinant vesicular stomatitis virus (rVSV) vectored vaccine for the prevention of Ebola virus disease in interim and fi nal reports. 4,5 Now global eff orts are also focused on Zika virus, another epidemic declared by WHO as a Public Health Emergency of International Concern 6 between February, 2016, and November, 2016 . Vaccine development has been initiated and several candidates have entered initial clinical testing. 7 During the World Economic Forum meeting a consensus emerged on the need for a new approach to public-private collaboration to address epidemics and for exploring the establishment of a new fi nancing mechanism. Now, CEPI-the Coalition for Epidemic Preparedness Innovations, a partnership between public, private, philanthropic, non-governmental, intergovernmental, and civil organisations, is launched on Jan 19 at the World Economic Forum's 2017 meeting. CEPI will be based in Oslo, Norway, with offi ces in the UK, India, and the USA, but will be a global organisation with partners on all continents. CEPI provides a new funding model for the development of vaccines against epidemic infectious diseases through pooling resources from several investors. This coalition will build a new system to advance the development of safe, eff ective, and aff ordable vaccines, ensuring that price is not a barrier to Comment access for populations most at need. This will off er the world an insurance policy against the growing threat from emerging infectious diseases. CEPI will fi ll the gap between the normative functions of WHO and the procurement and delivery mandate of Gavi, the Vaccine Alliance, and close an important gap in global health architecture.
CEPI has two main objectives: to advance vaccine candidates against priority pathogens and to build technical and institutional platforms that accelerate the R&D response to known or unknown pathogen emergencies. A description of how plans for CEPI developed and its business plan are outlined by one of us (J-AR) and representatives of the wider partnership in another report. 8 For known high-priority threats, as defi ned by the WHO R&D Blueprint list, 2 CEPI has a just-in-case strategy to push vaccine candidates from late preclinical through proof of concept and safety phase 2 trials. CEPI has decided to start by tackling Middle East respiratory syndrome coronavirus (MERS), Nipah virus infection, and Lassa fever, as well as scoping potential support for vaccines against Ebola (other strains than Zaire), Marburg, and Zika viruses. However, although CEPI knows these viruses could cause the next major outbreak, we are aware that it is more likely to arise from an unknown pathogen. Therefore, CEPI also has a just-in-time strategy, which aims to create the ability to respond quickly to new threats by investing in validating adaptable vaccine technology platforms and production facilities. CEPI needs to raise US$1 billion over 5 years to deliver on these strategies.
This emphasis on preventing and preparing for outbreaks, epidemics, and pandemics comes at a time when globalisation, urbanisation, and environmental and climate change mean that infectious diseases are increasingly global threats that respect no borders. Health protection is therefore dependent on investing collectively in global health security. The chain is no stronger than its weakest link. So the global community must invest in domestic capabilities that meet International Health Regulations requirements and establish core national capacities in all countries through building countries' workforce capabilities, strengthening real-time surveillance, and strengthening laboratory systems for earlier detection of potential threats. The global community must also invest in global capabilities such as the development of biomedical countermeasures. Although no-one knows what the next outbreak will be, we must develop the required arsenal now. No country can do this on its own. Countries need to invest in an insurance that collectively enables us to respond faster and mitigate risk to lives and livelihoods. CEPI is such a global health insurance mechanism. CEPI can achieve much more with pooled resources than any nation can achieve alone. Countries must invest together to generate global public goods. They need to act jointly because investments that protect the poorest people will make the world safer for all of us.
We represent the fi rst public and philanthropic funders to invest in CEPI. We have so far collectively committed about US$460 million to a pooled fund, and are working to mobilise more. The European Commission will contribute to CEPI's objectives and plans to co-fund actions with CEPI, such as through the Innovative Medicines Initiative. Together, we see such a coalition as an important investment for global epidemic preparedness. The impact of epidemics such as Zika virus, Ebola virus disease, and severe acute respiratory syndrome (SARS) on national and regional economies has shown that no country can aff ord not to invest in protection against outbreaks. However, more investors are needed-both to reach the US$1 billion over 5 years that would enable CEPI to realise this fi rst phase of its mission, and because the initiative will be most successful with participation from countries of all sizes, geographical regions, and levels of economic development. CEPI will have a crucial role in generating necessary global public goods for populations in need. Global health governance calls for institutional innovations that can operate with the public and private sectors, governments, and non-governmental organisations, and that can build on normative guidance from UN organisations, such as WHO, to develop technologies that can be procured by deliveryoriented global health organisations and regional and national government agencies. CEPI will fi ll this gap in global health R&D, and we welcome more partnersboth investors and implementers. 
Access to Medicine Index-what about sustainability?
A pharmaceutical company representative described the Access to Medicine Index 2016 as "a force for good, and not yet another stick with which to beat industry". 1 The Access to Medicine Index 2016, 1 which will be presented at a public meeting later this month at the time of the WHO Executive Board meeting in Geneva, ranks the top 20 research-based pharmaceutical companies on their eff orts to improve access to medicine in low-income and middle-income countries (LMICs). And those companies with high ranking tout their success to their stockholders and the media. 2 The Access to Medicine Index ranks pharmaceutical companies in areas that range from general access to medicine management and pricing, to product donations, patents, and licensing in a series of company report cards and summary comparison tables and graphs. It refers to aff ordability of medicines and sustainability of supply by diff erent end users: global funding mechanisms that depend on development agencies and other donors to provide and oversee use of their funds, and countries which negotiate pricing or local manufacture. Although the report describes some middle-income countries as the end user, it does not emphasise the importance of pharmaceutical pricing that makes it feasible for all countries to become an end user-a much tougher call, but the surest route to sustainable access to medicines. In addition, while generic medicines are vital for achieving sustainable access to medicines in LMICs, 3 generics producers are not included in the Index.
The Index also highlights successful product donations for diseases such as onchocerciasis, leprosy, lymphatic fi lariasis, and trachoma in countries where governments are engaged, sometimes working alongside nongovernmental organisations. Since the beginning of these donation programmes, the prevalence of targeted neglected tropical diseases has decreased, in some instances to reach global targets. [4] [5] [6] The Index recognises the need for countries to engage in providing access to these donated medicines, and rightly places much of the responsibility to deliver the medicines on countries themselves. At the same time, countries must consider how they will take over and sustain access as part of their national responsibility when these donation programmes come to an end.
The same can be said for country dependence on aid from mechanisms such as the Global Fund to Fight AIDS, Tuberculosis and Malaria, Gavi, the Vaccine Alliance, and UNITAID to provide their populations with access to medicine. These mechanisms depend on the 
